News

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

Keratosis pilaris has often been associated with AD and filaggrin loss-of-function mutations, the latter of which are frequent in Europe with an approximate prevalence of 7%

At DDW 2022, Dr. Sands highlights the positive findings from the LUCENT-1 study on the efficacy and safety of mirikizumab.

Patients treated with ustekinumab are not at an increased risk of malignancies.

Investigators led by Dr. Bowie deemed it necessary to establish “transparent classification” of topical corticosteroids in the pursuit of stronger and more reliable dermatologic outcomes and treatments.

Treating the disease could reduce the risk of patient distress.

The director of NIDA discusses the interplay of substance use disorder and pain in patients, as well as means to assure patients are receiving evidenced-based treatment.

Lois Choi-Kain, MD, MEd, discusses the unique presentations of disease and burdens of care that impact younger patients with BPD.

The modern psychiatrist may play many roles, including as a mentor and a facilitator to social-based support.

Prior to this new data, only 2 studies had evaluated the association between psoriasis and NAFLD in the US.

Investigators suggested that the large number of systemic therapies used when treating HS in these patients indicated referral delays or difficulties in obtaining disease control in those with moderate to severe HS.

There are several live microbiota therapeutics in development, including RBX2660.

Data show the safety profile of Ustekinumab in long-term IBD pooled safety dataset was found favorable among bionaive patients.

The treatment has previously been approved by the FDA for the treatment of ulcerative colitis.

A discussion on the role of PLSec-AFP for HCC risk stratification in patients with cirrhosis and future screening implementations.

The NIDA director reviews neuromodulation's potential role in treating patients with multiple use disorders, and the importance of patient feedback in shaping clinical research.

Rachel Talley, MD, discusses the industry-level changes needed to trainee recruitment and retention to create a psychiatry field more representative of its patient population.

Rates per 100 person-years for adverse events, infections, and major adverse cardiac events were similar between placebo and ustekinumab through up to 5 years.

The age of screening for colon cancer has decreased in recent years.

Dr. Dubinsky said new IL-23 treatments could enable precision medicine in the future for IBD.

The findings show EUS-CDL is more efficient than ERCP-M with comparable short-term effectiveness and safety.

New information suggests a few more cases have surfaced in the United States, pending CDC confirmation.

Data show the presence of five and six risk factors increased the risk of VTE exponentially to 10.9% and 25%, respectively

The treatment recently became the first ever FDA-approved medication for EoE.

With administration strategies for the psychiatric anesthetic drug well established, clinicians have interest in accumulating long-term data and other potential indications.

This approval makes tapinarof cream the first and only FDA-approved steroid-free topical medication in its class.

Despite this, more than half of nurses included in this global survey were not financially compensated for their additional work.

Brent Forester, MD, MSc, discusses the confluence of biomarker and disease-targeting therapy in Alzheimer's, and the need to appropriately introduce these tools.